Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

ShangPharma Obtains China Rights to Mabspace Antibody Technology

publication date: Nov 27, 2013
ShangPharma, one of China’s largest CROs, signed an exclusive China license agreement with Mabspace International to specific Mabspace antigens and technology for CRO use in antibody discovery. Founded in 2011, Mabspace discovers novel fast follow-on antibody-based therapeutic agents that target chronic kidney diseases, cancer and autoimmune disorders. Mabspace is headquartered in Hong Kong with a mainland subsidiary in Suzhou BioBay. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital